Breathlin SR200 mg

Breathlin SR 200 mg is a methylxanthine bronchodilator used mainly as a second- or third-line option, generally added when preferred inhaled therapies are insufficient. Indications are classified below by evidence strength.

• Established indication: Maintenance (symptomatic and prophylactic) treatment of chronic asthma, including nocturnal asthma and early-morning wheezing, in patients not adequately controlled by preferred inhaled therapies.
• Established indication: Maintenance treatment of reversible airflow obstruction associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
• Guideline-supported adjunct: Add-on bronchodilator therapy in asthma or COPD inadequately controlled on inhaled corticosteroids and/or long-acting bronchodilators, per current asthma/COPD management guidance, where inhaled options are unavailable, not tolerated, or insufficient — Breathlin SR 200 mg is not a preferred first-line agent in current guidelines.
• Requires-combination/adjunct use: Acute exacerbations of asthma or COPD, used together with (not in place of) short-acting bronchodilators and corticosteroids.
• Historical/specialist use (off-label in many settings): Apnea of prematurity, used historically under neonatology specialist supervision; caffeine citrate is generally preferred where available.

Breathlin SR 200 mg is not a rescue medicine for acute breathlessness and does not replace fast-acting inhalers.

Breathlin SR 200 mg is available in multiple pharmaceutical forms depending on brand and market, including immediate-release tablets, sustained-release/extended-release tablets or capsules, oral liquid (syrup/elixir), and injectable solutions. Common strengths include Breathlin SR 200 mg 100 mg, 200 mg, 300 mg, and 400 mg tablets/capsules, and Breathlin SR 200 mg oral liquid formulations such as 120 mg/5 mL. Exact composition and inactive ingredients vary by brand/manufacturer; refer to the specific product label for the precise formulation of Breathlin SR 200 mg being dispensed.

Breathlin SR 200 mg is a methylxanthine-derivative bronchodilator that has been used for decades in the management of asthma and chronic obstructive pulmonary disease (COPD). It relaxes bronchial smooth muscle, reduces airway responsiveness to stimuli, and modestly improves diaphragmatic contractility, thereby easing airflow obstruction. Because Breathlin SR 200 mg has a narrow therapeutic index — the difference between an effective dose and a toxic dose is small — its use requires individualized, often weight-based dosing with periodic monitoring of serum Breathlin SR 200 mg levels. In current asthma and COPD treatment guidelines, Breathlin SR 200 mg is generally reserved as a second- or third-line option after inhaled bronchodilators and corticosteroids.

Methylxanthine bronchodilator (xanthine derivative); anti-asthmatic/anti-COPD agent.

Breathlin SR 200 mg relaxes airway smooth muscle and suppresses the response of the airways to stimuli, producing bronchodilation. Proposed mechanisms include non-selective inhibition of phosphodiesterase enzymes (raising intracellular cyclic AMP), antagonism of adenosine receptors, and anti-inflammatory/immunomodulatory effects at higher concentrations. Breathlin SR 200 mg also stimulates the central respiratory drive and enhances diaphragmatic muscle contractility, which contributes to its historical use in apnea of prematurity. It is metabolized in the liver mainly via the CYP1A2 enzyme (with lesser involvement of CYP2E1 and CYP3A), giving it a large potential for drug interactions. Elimination half-life varies widely — roughly 3 to 9 hours in healthy adult non-smokers — but is prolonged in neonates, the elderly, and patients with hepatic impairment, heart failure, or febrile illness, and shortened in smokers and children.

Take Breathlin SR 200 mg exactly as prescribed and at consistent times each day, since food and timing can affect absorption of some formulations. Extended-release/sustained-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or split unless the specific product is scored for that purpose, as doing so can cause rapid release of the full dose and toxicity. Take doses either consistently with food or consistently without food, according to the specific product's instructions, rather than switching back and forth. If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose; do not double the dose. Do not change brands of Breathlin SR 200 mg without consulting the prescriber, since bioavailability can differ between products.

Breathlin SR 200 mg is metabolized mainly by the hepatic CYP1A2 enzyme and has numerous clinically significant drug interactions. The table below summarizes major interactions; this list is not exhaustive, and any new medicine (including over-the-counter products) should be discussed with a physician or pharmacist.

Side effects are generally dose-related and more likely as serum Breathlin SR 200 mg concentrations approach or exceed the therapeutic range. Common side effects include:

• Nausea, vomiting, and epigastric/abdominal discomfort
• Headache
• Nervousness, restlessness, and difficulty sleeping (insomnia)
• Tremor
• Increased heart rate and palpitations
• Increased urination (diuresis), particularly in children

Signs of more serious toxicity — persistent or repeated vomiting, marked tachycardia, irregular heartbeat, or seizures — require immediate medical attention (see Overdose Effects and Precautions and Warnings).

Pregnancy: Breathlin SR 200 mg crosses the placenta. Some animal reproduction studies have shown adverse fetal effects at high doses, and human data are limited; safety in pregnancy has not been firmly established. Breathlin SR 200 mg should be used in pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus, and only under a physician's guidance, generally with closer monitoring of serum levels as pregnancy can alter clearance.

Lactation: Breathlin SR 200 mg passes into breast milk at concentrations similar to maternal serum levels. Breastfed infants may experience irritability, feeding difficulty, or, rarely, signs of mild toxicity. Use during breastfeeding should occur only under medical supervision, with the infant observed for irritability or poor feeding; if the mother's Breathlin SR 200 mg level is within the toxic range, additional caution is warranted.

Breathlin SR 200 mg is a narrow therapeutic index drug: the difference between a therapeutic and a toxic dose is small, and toxicity (including serious arrhythmias and seizures) can occur even at levels only slightly above the therapeutic range. Periodic monitoring of serum Breathlin SR 200 mg concentration is essential, especially at treatment initiation, after any dose change, when signs of toxicity appear, or when a condition or medicine that affects Breathlin SR 200 mg clearance changes.

Use with particular caution in patients with:

• Uncontrolled cardiac arrhythmias
• Uncontrolled seizure disorders
• Active peptic ulcer disease
• Underlying heart disease, including heart failure or cor pulmonale
• Hyperthyroidism
• Hepatic impairment (reduces Breathlin SR 200 mg clearance and increases toxicity risk)
• Elderly patients (over 60 years), who generally clear Breathlin SR 200 mg more slowly
• High fever, acute febrile illness, or viral infections, which can reduce clearance

Any change in smoking status (starting, stopping, or significant change in amount smoked) alters Breathlin SR 200 mg clearance and requires dose reassessment by the prescriber — do not change smoking habits without informing the physician. Patients should limit caffeine and other xanthine-containing beverages or medicines, as these can add to Breathlin SR 200 mg's stimulant side effects. Whenever nausea, vomiting (especially repeated), rapid or irregular heartbeat, or other signs of toxicity occur, further doses should be withheld and medical advice sought immediately, ideally with a serum Breathlin SR 200 mg level check. Do not switch between Breathlin SR 200 mg brands or formulations without medical advice, as bioavailability can differ.

Breathlin SR 200 mg overdose or toxicity can be serious and, in severe cases, life-threatening. Early symptoms may include nausea, vomiting (often repeated), abdominal pain, headache, restlessness, and insomnia. As serum levels rise further, more severe effects can occur, including significant tachycardia, cardiac arrhythmias, marked hypotension, hyperglycemia, low blood potassium, seizures (which may occur without earlier warning symptoms, particularly with acute large overdoses), and, rarely, death. Because toxicity can progress rapidly and seizures can occur even without milder warning signs, any suspected Breathlin SR 200 mg overdose or signs of significant toxicity require immediate emergency medical attention. Treatment is supportive and may include activated charcoal (if appropriate and given promptly), cardiac monitoring, seizure management, and, in severe cases, measures to enhance Breathlin SR 200 mg removal under hospital care. Do not attempt to manage a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric patients: Breathlin SR 200 mg has a long history of approved use in pediatric asthma, but clearance varies greatly with age (highest relative doses often needed in young children, and reduced clearance in neonates and infants under one year), so pediatric dosing requires careful, individualized calculation and serum level monitoring; see Pediatric Uses.

Elderly patients: Breathlin SR 200 mg clearance is reduced in patients over 60 years, increasing the risk of toxicity at doses tolerated by younger adults; lower starting doses and closer monitoring are recommended.

Hepatic impairment: Breathlin SR 200 mg clearance can be reduced substantially in liver disease; dose reduction and more frequent serum level monitoring are needed.

Renal impairment: Breathlin SR 200 mg is primarily hepatically metabolized, so dose adjustment for renal impairment alone is generally not required, but caution is still advised in significant renal disease, especially with concurrent illness.

Smokers: Smokers metabolize Breathlin SR 200 mg faster and often need higher doses; conversely, if a patient stops smoking, clearance falls and the dose usually needs to be reduced to avoid toxicity.

Pregnancy and breastfeeding: See Pregnancy and Lactation.

Breathlin SR 200 mg is generally used as a long-term maintenance therapy for chronic asthma or COPD, with duration determined by the treating physician based on ongoing symptom control, lung function, tolerability, and periodic serum level monitoring. It is not intended for short-term relief of acute breathlessness. Any decision to continue, adjust, or stop Breathlin SR 200 mg therapy — including step-down as asthma/COPD control improves with other therapies — should be made in consultation with the prescribing physician, and should not be stopped or restarted abruptly without medical advice, since this can affect clearance and dosing needs.

Methylxanthines / Xanthine derivatives; Anti-asthmatic and anti-COPD bronchodilators.

Breathlin SR 200 mg produces bronchodilation mainly by relaxing airway smooth muscle and reducing airway hyperresponsiveness to stimuli. Proposed cellular mechanisms include non-selective inhibition of phosphodiesterase enzymes (increasing intracellular cyclic AMP in smooth muscle), antagonism of adenosine receptors, and, at higher concentrations, anti-inflammatory and immunomodulatory actions. It also stimulates the central respiratory drive and improves contractility of the diaphragm, supporting its historical use in apnea of prematurity. Onset and duration of effect depend on the formulation (immediate- versus extended-release) and on individual metabolic clearance via hepatic CYP1A2.

C

Breathlin SR 200 mg has an established history of use in pediatric chronic asthma, historically approved for symptomatic and prophylactic management in children who require ongoing bronchodilator therapy, and it has also been used under specialist supervision for apnea of prematurity. However, because of Breathlin SR 200 mg's narrow therapeutic index and highly age-dependent, unpredictable clearance in infants and young children, pediatric use requires careful individualized, typically weight-based dosing together with regular serum Breathlin SR 200 mg level monitoring. Neonates and infants under one year have reduced and variable clearance and are at higher risk of toxicity; use in this age group should occur only under close specialist (pediatric/neonatal) supervision. Parents/caregivers should watch for early signs of toxicity — persistent vomiting, unusual restlessness, rapid heartbeat — and seek prompt medical advice if these occur.